Home > Boards > US Listed > Biotechs >

Cellectar Biosciences Inc. (CLRB)

CLRB RSS Feed
Add CLRB Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/20/2020 8:54:04 PM - Followers: 118 - Board type: Free - Posts Today: 0

Image result for CELLECTAR


Product Pipeline

Multi-Asset Product Portfolio for Treatment of Various Cancers

Our proprietary phospholipid ether (PLE) platform technology features include the capacity to link to a wide variety of warheads, provide a significant increase in targeted oncologic warhead delivery and the ability to target all tumor cells. As a result, we're working to generate Phospholipid Drug Conjugates™ (PDCs) to treat a broad range of cancers with the potential to improve the therapeutic index of oncologic drug warheads, enhance or maintain efficacy while reducing adverse events by minimizing drug delivery to healthy cells, and increasing delivery to cancerous cells and cancer stem cells.

 

PDC Proprietary Product Pipeline

PDC PROGRAM WARHEAD/
MECHANISM OF ACTION
INDICATION DISCOVERY PRE-IND PHASE 1 PHASE 2 COLLABORATION
CLR 131 IODINE-131
DNA DAMAGE
MULTIPLE MYELOMA
DISCOVERY PHASE COMPLETE
PRE-IND PHASE COMPLETE
PHASE 1 PHASE COMPLETE
PHASE 2 PHASE IN PROGRESS
 
B-CELL LYMPHOMAS
DISCOVERY PHASE COMPLETE
PRE-IND PHASE COMPLETE
PHASE 1 PHASE COMPLETE
PHASE 2 PHASE IN PROGRESS
 
PEDIATRIC
DISCOVERY PHASE COMPLETE
PRE-IND PHASE COMPLETE
PHASE 1 PHASE IN PROGRESS
PHASE 2 PHASE NOT STARTED
University of Wisconson-Madison
HEAD & NECK
DISCOVERY PHASE COMPLETE
PRE-IND PHASE IN PROGRESS
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Univeristy of Wisconsin-Madison
CLR 1900 PROPRIETARY
CELL CYCLE ARREST
SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
 

Partnerships

PDC PROGRAM WARHEAD/
MECHANISM OF ACTION
INDICATION DISCOVERY PRE-IND PHASE 1 PHASE 2 COLLABORATION
CLR 1800 PROPRIETARY
TRANSLATION INHIBITION
SOLID TUMORS
DISCOVERY PHASE COMPLETE
PRE-IND PHASE IN PROGRESS
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Pierre Fabre
CLR 2000 PROPRIETARY
CYTOSKELETON DISRUPTION
PERFORMANCE-BASED
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Avicenna Oncology
CLR 2100 PROPRIETARY
RIBOSOMAL INHIBITOR
SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Onconova Therapeutics
CLR 2200 PROPRIETARY
TUBULIN DISRUPTION
SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
Onconova Therapeutics
CLR 12120   SOLID TUMORS
DISCOVERY PHASE IN PROGRESS
PRE-IND PHASE NOT STARTED
PHASE 1 PHASE NOT STARTED
PHASE 2 PHASE NOT STARTED
oranomed

Proprietary Products

CLR 131

CLR 131 is a small-molecule, targeted PDC designed to deliver cytotoxic radiation directly and selectively to cancer cells. CLR 131 is our lead therapeutic PDC product candidate and is currently being evaluated in multiple Phase 2 and Phase 1 clinical studies. 
VIEW CANDIDATE

CLR 1700

CLR 1700 series is an internally developed PDC program leveraging a unique warhead targeting Burton tyrosine kinase (BTK) and designed to treat a broad range of hematologic cancers. The warhead provides further specificity by targeting the BTK pathway, which is upregulated in hematologic cancers versus in comparison to normal tissue. We believe that this additional level of targeting will allow us to provide a new drug candidate that has the ability to significantly improve patient outcomes. Leveraging our iterative discovery and screening process, we have been able to rapidly accelerate the development of this program. Currently marketed BTK inhibitors generate >$4B in revenues per year.

CLR 1900

CLR 1900 series is another internally developed proprietary PDC program leveraging a novel class of small molecule cytotoxic compounds as the warhead. The warhead functions by targeting a validated pathway that results in the inhibition of cell division and thereby killing the tumor cells. This series of molecules could produce a product candidate targeted to select solid tumors. Currently, the program is in early preclinical development.


Partnered Products

CLR 1800

CLR 1800 series is part of a collaborative PDC program with Pierre Fabre, the third largest French pharmaceutical company with an extensive oncology research and development infrastructure. The objective of the research collaboration is to design a library of PDCs employing Pierre Fabre's chemotherapeutics in combination with our proprietary cancer-targeting delivery vehicle. The newly developed PDCs may provide enhanced therapeutic indices to otherwise highly potent, non-targeted warheads through the targeted delivery to cancer cells. Significant progress has been achieved and the program continues to rapidly advance with a number of PDC molecules showing enhanced pharmacologic behavior over the parent compound alone.

CLR 2000

CLR 2000 series is part of a collaborative PDC program with Avicenna Oncology, a leading developer of antibody drug conjugates (ADCs). The objective of the research collaboration is to design and develop a series of PDCs utilizing Avicenna Oncology’s proprietary cytotoxic warhead. Although Avicenna Oncology is a leading developer of ADCs, this collaboration was sought as a means to overcome many of the challenges associated with ADCs, including those associated with the targeting of specific cell surface epitopes.

CLR 2100 and 2200

CLR 2100 and 2200 series are part of a collaborative PDC programs with Onconova Therapeutics, Inc., a biotechnology company specializing in the discovery and development of novel small molecule cancer therapies. The collaboration is structured such that we will design and develop a series of PDCs utilizing different small molecules that Onconova Therapeutics is developing as the warheads with the intent to show improved targeting and specificity to the tumor. Onconova Therapeutics has previously taken at least one of the molecules into Phase 1 clinical trials.

CLRB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#8026   snakeoil company just disappear instantly. Sunofwolf 11/20/20 08:54:04 PM
#8025   What a big winner this company will be, Crusader 11/20/20 07:27:55 AM
#8024   what a loser this company is! Sunofwolf 10/25/20 12:28:05 AM
#8023   Ya watching it go down every day, this Sunofwolf 09/30/20 02:40:29 AM
#8022   Watching this one. PENNYBUSTER 09/27/20 01:12:30 PM
#8021   must be insider trading which is illegal! Sunofwolf 09/21/20 11:27:43 AM
#8020   LBO? Crusader 09/20/20 11:55:22 PM
#8019   Crusader, Something big is going on behind the scenes.. Jakhoub 09/19/20 12:08:18 PM
#8018   CLRBZ: up over 700% Crusader 09/18/20 11:25:10 PM
#8017   SBOX, Why do you think the "z" warrantS skyrocketed today? Jakhoub 09/18/20 05:12:04 PM
#8016   Improves the ORR in all MM populations previous Sluicebox 09/18/20 04:13:39 PM
#8015   Bouncing off the EM2. swingingRichard 09/15/20 12:11:32 PM
#8014   Vol tells everything. Sunofwolf 09/15/20 05:55:08 AM
#8013   News release is nothing more than miss info- Sunofwolf 09/15/20 05:54:23 AM
#8012   CLRB on watch here Longer Than Most 09/09/20 02:41:35 PM
#8011   NEWS: 40% ORR Crusader 09/09/20 10:45:51 AM
#8010   Cellectar can beat that ! Belantamab just approved Sluicebox 08/07/20 09:59:19 AM
#8009   Looking very much forward to their pediatric neuro Sluicebox 08/07/20 04:00:51 AM
#8008   Too easy to manipulate, and too many short Sluicebox 08/07/20 03:52:05 AM
#8007   suk you in then thing falls like a meteor-LOL! Sunofwolf 08/04/20 02:36:48 PM
#8006   Nice Day Heading Higher. PENNYBUSTER 07/30/20 04:50:38 PM
#8005   some worthless news, to get people to buy Sunofwolf 07/30/20 10:28:08 AM
#8004   Great volume premarket on cancer news Should see daddydo 07/30/20 07:49:30 AM
#8003   On Radar! PENNYBUSTER 07/29/20 11:35:48 PM
#8002   Some highlight from the paragraph about CLR-131. Sluicebox 07/28/20 09:44:07 AM
#8001   That doesn't make Cellectar a fraud :-) just Sluicebox 07/28/20 09:42:36 AM
#8000   That doesn't make Cellectar a fraud :-) just Sluicebox 07/28/20 09:42:34 AM
#7999   Why I know this company is a fraud. Sunofwolf 07/26/20 02:10:19 PM
#7998   Pt Barnum had a famous quote- (a sucker Sunofwolf 07/26/20 02:04:09 PM
#7997   European patent granted !! Loading up shares. Sluicebox 07/22/20 02:44:40 PM
#7996   Great news, god to see them making some Sluicebox 07/22/20 01:42:52 PM
#7995   Why do you think this company is a Sluicebox 07/22/20 01:37:15 PM
#7994   company is a scam, nothing here butt losers. Sunofwolf 07/12/20 11:38:43 PM
#7993   Yes there is a big chance that CLR131 Sluicebox 07/10/20 06:58:10 PM
#7992   Yes there is a big chance that CLR131 Sluicebox 07/10/20 06:58:08 PM
#7991   What’s up here, traders? Crusader 07/09/20 12:39:48 PM
#7990   What’s up here, traders? Crusader 07/09/20 12:39:48 PM
#7989   Ups you'r right. Sluicebox 07/08/20 04:32:53 AM
#7988   He got free options (not a buy): Rymankoly 07/06/20 04:13:10 PM
#7987   VP CMO buys 100000 shares at 1.34. I Sluicebox 07/06/20 08:55:09 AM
#7986   New PT from Oppenheimer $5 outperform Sluicebox 07/01/20 08:57:44 AM
#7985   It's a real shame about the watering out Sluicebox 06/30/20 08:19:47 AM
#7984   correct its only purpose is to pay for Sunofwolf 06/26/20 11:19:37 AM
#7983   Cellectar is garbage! Jonnyo07 06/24/20 09:57:28 AM
#7982   7:44 am ET June 23, 2020 stockguard 06/23/20 02:29:46 PM
#7981   Finally - money on the book to drive Sluicebox 06/11/20 12:39:53 PM
#7980   Company selling shares, most likely. Most bios are in S3lfMade 05/26/20 03:38:35 PM
#7979   Why did it take a nose dive on cash_cow1 05/26/20 12:08:02 PM
#7978   CLR 131 is a radiotherapy designed to directly S3lfMade 05/26/20 09:02:48 AM
#7977   $5 Clover study of CLR131? Crusader 05/26/20 08:51:22 AM
PostSubject
Consent Preferences